SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced a new exclusive Zingo(TM) marketing and distribution agreement, with Green Vision Company, for several Middle Eastern countries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the U.S. to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.
Green Vision is a pharmaceutical company headquartered in Qatar. The agreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates. Green Vision will be responsible for obtaining and maintaining product registrations in the licensed territories, as well as sales and marketing in the region. Terms of the agreement include an upfront payment, regulatory and sales milestones and royalty payments.
"This agreement further extends the potential markets for Zingo, a needle-free, local analgesic with a rapid onset of action, prior to peripheral venous access procedures in children, and is further validation of the unmet need Zingo addresses," said John P. McLaughlin, Anesiva's chief executive officer.
Zingo(TM) is an easy-to-administer, single-use, needle-free system that
delivers sterile lidocaine powder to provide topical, local anesthesia to
reduce the pain associated with peripheral IV insertions or blood draws.
Zingo's rapid onset of action allows intravenous line placement or
venipuncture to begin one to three minutes after administration. Zingo is
approved in the U.S. to reduce the pain associated with peripheral IV
insertions or blood draws in children three to 18 years of age. In clinical
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved